Editors' ChoiceCancer

Fighting leukemia with “duel”-targeted therapy

See allHide authors and affiliations

Science Translational Medicine  04 Apr 2018:
Vol. 10, Issue 435, eaat3887
DOI: 10.1126/scitranslmed.aat3887

You are currently viewing the abstract.

View Full Text

Abstract

Combining BCL-2 inhibitor venetoclax with monoclonal CD20 antibody rituximab greatly enhances progression-free survival compared with bendamustine-rituximab in a phase 3 trial of relapsed or refractory chronic lymphocytic leukemia patients.

View Full Text